Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ephedra seizure

This article was originally published in The Tan Sheet

Executive Summary

U.S. Marshals seized nearly 3,000 bottles of Nature's Treat Energy Plus #1, a dietary supplement containing ephedra, FDA announces Dec. 6. The U.S. Attorney's Offices for the Eastern District of Texas and for the District of Oregon filed complaints of forfeiture at the agency's request, FDA adds. The seized products have a retail value of about $150,000. FDA banned supplements containing ephedrine alkaloids in 2004 and is now appealing a Utah District Court decision finding that Nutraceutical Corp. may continue selling its 10 mg product ("1The Tan Sheet" Nov. 14, 2005, p. 4)...

You may also be interested in...

“No Evidence” Exists That Ephedra Ban Shifted Burden Of Proof, Agency Says

No evidence has been presented that FDA's use of a risk/benefit analysis in its decision to ban ephedra shifted the burden of proof onto industry, the agency says

Finance Watch: Two SPAC Deals, Two IPOs Take Four Biopharmas Public

Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.

#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity

Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts